CYRX Earnings Prediction
The chart below shows how CYRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CYRX sees a +8.79% change in stock price 10 days leading up to the earnings, and a +0.29% change 10 days following the report. On the earnings day itself, the stock moves by +0.85%. This data can give you a slight idea of what to expect for the next quarter's release.
CYRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
59.53M
3.97%
5.06%
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
CYRX Earnings Analysis
Cryoport Inc Corporation (CYRX.O) Earnings Conference Call
Positive
Annual Revenue Achievement: Total annual revenues for 2024 reached $228.4 million, aligning with expectations.
BioStorage and BioServices Growth: Life Sciences Services business experienced double-digit year-over-year growth in BioStorage and BioServices revenue for both the fourth quarter and full year.
Commercial Therapy Support Growth: Support for commercial cell and gene therapies rose by 37% in Q4 and 20% for the full year.
Clinical Trials Milestone: Cryoport supported a record total of 701 clinical trials, with a net increase of 26 trials over the previous year, including 81 in Phase 3.
Commercial Program Growth: The number of commercial programs supported by Cryoport increased from 14 to 19, indicating growth in commercial approvals.
Gross Margin Improvement: Gross margin improved to 45.8% in Q4 2024, up from 40.6% in the same period last year, reflecting effective cost management initiatives.
New Product Launch Revenue: The IntegriCell cryopreservation solution was launched with new facilities in Houston and Liege, expected to generate significant revenue.
Cryogenic Shipping System Launch: The Cryoport Express Cryogenic CXHV3 shipping system was introduced, enhancing patient accessibility to cell therapies.
2025 Revenue Projections: Projected revenue guidance for 2025 is between $240 million to $250 million, indicating anticipated growth.
Strong Start to Year: Three filings have already occurred in January 2025, signaling a strong start to the year.
Negative
Earnings Miss Report: Cryoport, Inc. misses on earnings expectations with a reported EPS of $-0.42, while expectations were $-0.33.
Market Challenges in Life Sciences: 2024 was described as a tough year for life sciences, indicating challenges in the market.
Underwhelming Revenue Performance: Despite total annual revenues of $228.4 million being in line with expectations, the overall performance was still underwhelming given the macroeconomic conditions.
Cryogenic Market Downturn: The company faced a downturn in the cryogenic systems market, which could impact future revenue streams.
Gross Margin Improvement Challenges: While gross margin improved to 45.8%, this was in the context of cost management initiatives, suggesting underlying challenges in profitability.
Cost Reduction Strategies: The need for cost reduction and capital realignment strategies indicates financial strain within the company.
Positive EBITDA Projection: The company is projecting a return to positive adjusted EBITDA in 2025, highlighting current operational difficulties.
Reactive Adaptation Challenges: The statement about adapting to challenges suggests that the company is still in a reactive mode rather than a proactive growth phase.
CYRX FAQs
How does CYRX typically perform around its earnings report dates?
Is Cryoport Inc (CYRX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CYRX Earning Call Sentiment
Cryoport, Inc. (NASDAQ:CYRX) Q4 2024 Earnings Call Transcript
CYRX.O
-10.39%Positive
The earnings call highlights positive elements such as revenue growth in Life Sciences Services and improved gross margins, but also notes an EPS miss and macroeconomic challenges. While optimistic guidance for 2025 and cost-saving measures are positives, the lack of a share repurchase program and unclear management responses in the Q&A create uncertainty. The absence of a market cap suggests a neutral stock reaction, as the positive and negative factors balance each other out.
